Subsidiaries plan Rs 43 crore capacity expansion by March 2027
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.8 pts less than Nifty Microcap 250 and 8.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Senores said its subsidiaries plan to expand plants. US-based Havix Group will lift annual capacity from 1.2 billion to 2.0 billion units at a cost of Rs 18 crore. Apnar Pharma will expand from 0.5 billion to 1.2 billion units for Rs 20 crore. Ratnatris will add a 2.7 million-unit prefilled syringe line for Rs 5 crore. Spending totals Rs 43 crore. Havix and Apnar will use internal accruals and IPO proceeds. Target completion is March 2027.
Higher capacity could support future sales, but Rs 43 crore of spending creates execution risk and may not deliver returns on time.